<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01023425</url>
  </required_header>
  <id_info>
    <org_study_id>2008-02-072</org_study_id>
    <nct_id>NCT01023425</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Donepezil Between the Naive Group and the Switching Group</brief_title>
  <official_title>Comparative Assessment of Clinical Efficacy of Donepezil Between the Naive Group and the Switching Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Korea Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the clinical efficacy of donepezil between the naive group and the switching
      group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purposes of this study are:

        1. to compare the efficacy between switching patients with Alzheimer's disease (AD) from
           galantamine or rivastigmine to donepezil because they were not responding adequately,
           and naive patients with AD who initiated therapy with donepezil

        2. to help to clinicians in choosing the best treatment
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale-Cognitive, Korean version (ADAS-Cog-K)</measure>
    <time_frame>13 weeks, 26 weeks, 39 weeks, 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seoul Activities of Daily Living (S-ADL)</measure>
    <time_frame>13 weeks, 26 weeks, 39 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seoul-Instrumental Activities of Daily Living (S-IADL)</measure>
    <time_frame>13 weeks, 26 weeks, 39 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Korean Neuropsychiatric Inventory (K-NPI)</measure>
    <time_frame>13 weeks, 26 weeks, 39 weeks, 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>switching group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>switching patients with Alzheimer's disease(AD) from galantamine or rivastigmine to donepezil because they were not responding adequately</description>
  </arm_group>
  <arm_group>
    <arm_group_label>naive group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>naive patients with AD who initiated therapy with donepezil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>donepezil</intervention_name>
    <description>from 5mg to 10mg, once a day, 12 months</description>
    <arm_group_label>switching group</arm_group_label>
    <arm_group_label>naive group</arm_group_label>
    <other_name>donepezil-aricept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A diagnosis of probable AD according to the criteria of the NINCDS-ADRDA

          2. Korean version Mini-Mental State Examination scores between 10 and 26

          3. History of cognitive decline that had been gradual in onset and progressive over at
             least 6 months

          4. A caregiver who could assist the patient with medication, attend the assessment and
             provide information about the patient.

        Exclusion Criteria:

          1. they had evidence of any neurodegenerative diseases other than AD (i.e. Parkinson's
             disease, Huntington's disease)

          2. Psychiatric disorder or severe behavioral disturbances that required psychotropic
             medications

          3. Cerebral injuries induced by trauma, hypoxia, and/or ischemia

          4. Clinically active cerebrovascular disease; History of seizure disorder

          5. Other physical conditions that required acute treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doh Kwan Kim, PhD, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2009</study_first_submitted>
  <study_first_submitted_qc>December 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2009</study_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Doh Kwan Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>naive group</keyword>
  <keyword>switching group</keyword>
  <keyword>treatment response</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Adverse event</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

